AJMC - The American Journal of Managed Care’s Post

Dr. Douglas Beall discusses sacroplasty and the importance of measuring clinical outcomes to mitigate criticism and validate your work. Despite skepticism from others about working outside their specialty, they have conducted 58 clinical trials and maintain four simultaneous registries. By collecting data, they demonstrate significant improvements in patient outcomes, such as reducing pain scores and helping patients reduce opioid use, thereby providing evidence of their effectiveness. Stream the full episode: https://ow.ly/HiGz50SwmFk #VI456 #MSK #MSKRadiology #InterventionalSpine #SpineIntervention #MinimallyInvasive #Osteoporosis #SacralInsufficiency #SacralFracture

Join us this THURSDAY for Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

#DidYouKnow that MASH is the leading cause of liver-related morbidity and can cause fibrosis and scarring which can lead to cirrhosis? Currently, there is only one therapy approved for the treatment of MASH which underlines the urgent unmet need for additional treatment options for these patients. At Aligos, we are developing ALG-055009, a THR-β agonist, as a potential best-in-class #MASH treatment. Learn more about our approach to advancing patient care (bit.ly/3A9M1Tv) and check out this article by The New York Times for a deeper look into the rising impact of MASH: bit.ly/3YGvw9R #LiverAwarenessMonth #LiverDisease

Atopic dermatitis (AD) that is on the hands 🖐️ isn’t the same as chronic hand eczema (CHE). They’re different—clinically and etiologically. See more about clinical presentation, etiological differentiators, and patient statistics at https://brnw.ch/21wPfff. #Eczema #AtopicDermatitis #HandEczema #ChronicHandEczema

▶️📈 Exciting Research from #TargetRWE at #ACG2024! A. Sidney Barritt IV, MD, MSCR, lead author and member of the #TARGETNASH steering committee, presented groundbreaking findings at the American College of Gastroenterology 2024 on the real-world impact of specific medications in patients with #MASLD. In this presentation, Dr. Barritt shares insights from the TARGET-NASH cohort, exploring the association between medication use and key #PatientOutcomes, including #Mortality and #DiseaseProgression. 🔍 Watch now to learn about the latest findings and their potential to change patient care: https://lnkd.in/gwUtRPVN  #ClinicaResearch #LiverDisease #HealthcareInnovation #LiverResearch #RealWorldEvidence #RealWorldData 

Avapritinib offers a new hope for advanced systemic mastocytosis, combining precision medicine with cost-effectiveness to improve patient outcomes. #PrecisionMedicine #ClinicalResearches #HealthcareInnovation #MarketAccessToday #MarketAccess

🔍 Another great presentation highlighting the exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/e_CcmDX8 #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024

Join us for our upcoming webinar, Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

Our recent study demonstrated that the combination of LIVERSTAT and Fibroscan offers a powerful one-step assessment for MASLD-related fibrosis. This combination: ✅ Identifies twice as many advanced fibrosis (F3F4) cases compared to the traditional FIB-4 and Fibroscan combo. ✅ Eliminates the "grey zone" in detection, ensuring no F3F4 patients are missed.
 ✅ Detects 41% of F3F4 cases missed by FIB-4. This streamlined approach offers a more accurate and efficient tool for early fibrosis identification, helping to ensure timely intervention and improved patient outcomes. Find out more about the study: https://zurl.co/9MQQ #MASLD #LIVERSTAT #Fibroscan #AdvancedFibrosis #LiverHealth #MASH

A big thank you to Cystic Fibrosis Trust for sharing this exciting update! Recent clinical trials show that a new triple combination modulator therapy, ‘Vanza Triple’, could offer additional benefits for some people with cystic fibrosis (CF) compared to Kaftrio. 🔎 Developing better modulator therapies is crucial to provide more treatment options and help more individuals with CF experience improved health outcomes. Find out more about Vanza Triple and what it could mean for the CF community by reading the full article here: https://lnkd.in/g9d7fMW3 #CysticFibrosisAustralia #CFA #VanzaTriple #Kaftrio #CysticFibrosis #CFResearch #CysticFibrosisAwareness